Program
narazaciclib
Also written as “HX301+/Temozolomide”, “HX301” and “Narazaciclib”.
Its studies are mostly in Glioma · Endometrial Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Hanx Biopharmaceuticals | 21 open or running | phase 2since Nov 21, 2024 | Jan 29, 2023 | Dec 31, 2026phase 2 · NCT06703255 |
| Traws Pharma | 22 open or running | phase 2since Jan 19, 2023 | Jan 29, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2021First study: phase 1 study in Solid Tumors, AdultNew to Traws PharmaTraws Pharma · NCT04739293 · 36 planned · United States
- Jan 19, 2023Phase 2 study in Endometrioid Endometrial CancerTraws Pharma · NCT05705505 · 60 planned · United States
- Jan 29, 2023Hangzhou Hanx Biopharmaceuticals's first study: phase 1 study in Advanced Solid TumorsNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT05731934 · 20 enrolled · China
- Nov 21, 2024Phase 2 study in GliomaHangzhou Hanx Biopharmaceuticals · NCT06703255 · 72 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in GliomaHangzhou Hanx Biopharmaceuticals · NCT06703255
TargetBeta
“An orally bioavailable inhibitor of NUAK family SNF1-like kinase 1 (AMPK-related protein kinase 5; ARK5), and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06703255Glioma · China | 2 | Recruiting | Hangzhou Hanx Biopharmaceuticals | Dec 31, 2026 | 72 |
| NCT05731934Advanced Solid Tumors · China | 1 | Completed | Hangzhou Hanx Biopharmaceuticals | Jan 12, 2024 | 20 |
| NCT05705505Endometrioid Endometrial Cancer · United States | 2 | Recruiting | Traws Pharma | Jan 2026 | 60 |
| NCT04739293Solid Tumors, Adult · United States | 1 | Recruiting | Traws Pharma | Oct 2024 | 36 |
How it is read
Names in the registry
- “HX301+/Temozolomide”, 1 entry
- “HX301”, 1 entry
- “Narazaciclib”, 1 entry
- “ON123300”, 1 entry
Conditions, from the studies’ own filings
- Glioma, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.